Chemotherapy: new uses for old drugs

Area of Science:

• Oncology
• Pharmacology
• Cancer Biology

Background:

• Chemotherapy drugs are being repurposed as antiangiogenic agents.
• Metronomic chemotherapy, a low-dose continuous schedule, offers a potentially favorable toxicity profile and reduced cost.
• This approach targets tumor angiogenesis, the formation of new blood vessels that feed cancer growth.

Purpose of the Study:

• To explore the potential of metronomic chemotherapy as an antiangiogenic strategy.
• To identify challenges and areas for future research in optimizing metronomic chemotherapy.
• To highlight promising biomarkers for monitoring treatment response.

Main Methods:

• Review of existing literature on metronomic chemotherapy and antiangiogenesis.
• Analysis of challenges in determining optimal drug selection, dosage, and scheduling.
• Exploration of potential response monitoring strategies.

Main Results:

• Metronomic chemotherapy presents an appealing option due to its toxicity profile and cost-effectiveness.
• Significant challenges remain in defining optimal treatment parameters for various tumor types.
• Biomarkers like angiogenic factors and circulating endothelial progenitor cells show promise for response assessment.

Conclusions:

• Metronomic chemotherapy is a promising antiangiogenic strategy requiring further investigation.
• Optimal tumor types, drugs, doses, schedules, and response monitoring endpoints need to be established.
• Measuring angiogenic factors and endothelial progenitor cells may aid in treatment evaluation.